Use of reduced dose of OKT3 (2.5 mg) after renal transplantation.
Machado
P G P
PG
Escola Paulista de Medicina, UNIFESP, Sao Paulo, Brazil.
Tedesco
H S
HS
Silva
R G
RG
Pacheco-Silva
A
A
Medina
J O P
JO
D000208:Acute Disease; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D012086:Reoperation; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors; D017211:Treatment Failure
D016853:Muromonab-CD3; D016559:Tacrolimus